Global Oncology Academy

Part 1: Improving Risk-based Management Decisions in Follicular Lymphoma

Part 1: Improving Risk-based Management Decisions in Follicular Lymphoma

How can clinicians use shared decision-making to close key gaps and improve outcomes for patients with relapsed/refractory follicular lymphoma?

Available credits: 0.50

Time to complete: 30 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    The anti-CD20 antibody rituximab has been the backbone of initial treatment for previously untreated follicular lymphoma (FL). The treatment options for FL are expanding, with multiple novel agents now approved by the US Food & Drug Administration in first-line and relapsed/refractory disease settings and others in late-stage trials. Despite advances in first-line care, treatment relapses commonly occur, with approximately 20% of patients experiencing relapse within 2 years; these patients have a 5-year overall survival of only 50%. Patients who present with earlier relapse are particularly challenging to treat because they often have more aggressive disease and will be exposed to multiple lines of therapy to attain disease control, and thus early progression predicts poor prognosis.

    A recent retrospective, exploratory analysis demonstrated the earlier the disease progression within the first 24 months (POD24), the higher the mortality risk, highlighting the need to identify patients at risk for early progression and who may benefit from first-line treatment that has demonstrated a relative risk reduction in early disease progression, such as obinutuzumab. These results represent important advances in the treatment of FL to reduce the rate of early disease progression. Disease and patient characteristics more commonly associated with higher POD24 have also been identified, which may assist in treatment planning.

    The advent of an expanding treatment armamentarium for FL and the complexities surrounding treatment strategies make FL a highly preference-sensitive disease. Introducing shared decision-making (SDM) can facilitate communication among clinicians, patients, and caregivers and allows for treatment plans to be co-created with patient goals, preferences, and values at the center of care planning.

    This activity aims to close key practice gaps and improve patient-physician communication by providing oncologists, hematologists, and other healthcare providers with education focused on the recent advances and critical concepts that affect outcomes, including survival, choice of therapy based on risk stratification, early disease progression, response criteria, and quality of life for their patients with FL.

    A patient and clinician SDM support tool will be provided to help foster discussion and dialogue that will result in improved SDM among patients, clinicians, and caregivers that is reflective of their needs, desires, and perspectives.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Utilize risk stratification models and guideline recommendations to make appropriate risk-based management decisions for the initial treatment of FL
    • Examine available evidence regarding identifying patients at risk for early progression and treatment options that may reduce the risk of early disease progression
  • Target Audience

    This activity is intended for community-based hematologists, physician assistants, nurse practitioners, pharmacists, and other healthcare professionals who treat or manage patients with follicular lymphoma.

  • Faculty Disclosures

    Disclosure of Conflict of Interest 

    AXIS Medical Education requires instructors, planners, managers, reviewers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity. Timothy Fenske, MD, MS, reported a financial interest/relationship or affiliation in the form of Speaker: AstraZeneca Pharmaceuticals LP; Celgene Corporation / Bristol-Myers Squibb; Adaptive Biotechnologies; Genentech, Inc; and Seattle Genetics, Inc. Consultant: AbbVie; MorphoSys AG; Verastem Oncology; and Kite Pharma.

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS;  Joseph Kim, MD, MPH, MBA;  Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; and Adrienne N. Nedved, PharmD, MPA, BCOP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. 

  • Accreditation and Credit Designation Statements

    Accreditation Statement

    ReachMD Healthcare Image

    In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Q Synthesis LLC. AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    ReachMD Healthcare Image

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ReachMD Healthcare Image

    Credit Designation for Physician Assistants
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 11/23/2021. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.5 contact hour of continuing pharmacy education credit JA4008106-9999-20-044-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Provider

    Jointly provided by ReachMD Healthcare Image and ReachMD Healthcare ImageReachMD Healthcare Image

  • Commercial Support

    Supported by educational grants from Bristol-Myers Squibb Company and Genentech, a member of the Roche Group.

  • Terms of Use

    Disclosure of Unlabeled Use      
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Method of Participation and Request for Credit:   
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free